Analyst firms · UBS · GOSS
UBS GOSS price target and rating history
Gossamer Bio Inc. (GOSS) · Health Care
UBS rates Gossamer Bio Inc. (GOSS) Buy with a $9 price target, as of its latest action on Sep 10, 2025. It has published 3 rating actions on GOSS since April 2022, including 1 upgrade and 1 downgrade. Across 4 firms with a GOSS price target in the last 12 months, the median target is $1.
- Current rating
- Buy
- Price target
- $9
- Median target, all firms
- $1
- Actions on GOSS
- 3
UBS price target on GOSS
Every UBS rating on GOSS
- Sep 10, 2025
- Jul 27, 2023
- Apr 6, 2022
How other firms rate GOSS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Chardan Capital Markets | Buy | $160 | Oct 13, 2026 |
| Leerink Partners | Outperform | $1 | Jul 28, 2026 |
| Cantor Fitzgerald | Neutral | Mar 23, 2026 | |
| Wedbush | Neutral | $1 | Feb 24, 2026 |
| Barclays | Equal Weight | $0.30 | Feb 24, 2026 |
Questions about UBS and GOSS
- What is UBS's price target for GOSS?
- UBS's latest stated price target for Gossamer Bio Inc. (GOSS) is $9, from its action on Sep 10, 2025.
- What is UBS's rating on GOSS?
- UBS rates GOSS Buy, a bullish rating, as of Sep 10, 2025.
- When did UBS last change its view on GOSS?
- On Sep 10, 2025, UBS upgrades to Buy from Neutral, price target $9.
- How does UBS's GOSS target compare with other analysts?
- Across 4 firms with a GOSS price target in the last 12 months, the median target is $1.
More GOSS rating histories
All UBS ratingsGOSS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.